MYC and prostate carcinoma: The Aurora A kinase inhibitor Alisertib showed a limited efficacy in initial studies in prostate cancer [96] and this inhibitor promotes the DFG-out state, but its efficacy is limited by the level of N-MYC overexpression in tumor cells; the Aurora A kinase inhibitor AMG-900 is a strong DGF-out inducer and might be more effective in displacing N-MYC and in inducing an antitumor effect [693].